◆ TICKERBASE交互式视图 →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

首页全部股票 › IQV · English version

IQVIA Holdings Inc (IQV)

来自官方财务报表的收入、利润与现金流历史。

Health Care · 华尔街(美国) · 最近更新: 2026-09-15

IQVIA Holdings Inc. 为美洲、欧洲、非洲和亚太地区的生命科学和医疗保健行业提供临床研究服务、商业见解和医疗保健情报。它通过三个部门运营:技术与分析解决方案、研究与开发解决方案以及合同销售与医疗解决方案。技术与分析解决方案部门提供一系列基于云的应用程序和相关实施服务;现实世界的解决方案,使生命科学和提供商客户能够生成和传播证据,为医疗保健决策提供信息并改善患者的治疗结果;战略和实施咨询服务,例如高级分析和商业流程外包服务。该部门还提供与医药产品销售、处方趋势、医疗和各种渠道(包括零售、医院和邮购)促销活动相关的国家级绩效指标;衡量地区、邮政编码和个人处方者级别的销售或处方活动。研究与开发解决方案部门提供项目管理和临床监测;临床试验支持;战略规划和设计服务;以患者和现场为中心的解决方案,以及中心实验室、基因组、生物分析、ADME、发现、疫苗和生物标志物实验室服务。合同销售和医疗解决方案部门提供医疗保健提供商和患者参与服务以及科学策略和医疗服务。它为制药、生物技术、设备和诊断以及消费者健康公司提供服务。公司与科兴生物医药有限公司达成生物类似药开发战略合作

机器翻译

关键数据

查看交互式图表与完整报表 → 估值模型 (DCF) →

年度利润表

利润表TTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
总收入$17.0B$16.3B$15.4B$15.0B$14.4B$13.9B$11.4B$11.1B$10.4B$9.7B$6.8B$5.7B$5.5B$5.1B$4.9B$4.3B$3.9B
毛利$4.5B$4.3B$5.4B$5.2B$5.0B$4.6B$3.9B$3.8B$3.7B$3.4B$2.1B$1.6B$1.5B$1.3B$1.2B$1.1B$1.1B
毛利率%26.2%26.3%34.9%35.0%34.9%33.5%34.0%34.2%35.2%35.0%30.3%28.3%27.5%26.2%25.3%26.4%28.5%
营业利润(EBIT)$2.3B$2.3B$2.2B$2.0B$1.8B$1.4B$731M$777M$741M$719M$642M$647M$590M$462M$396M$345M$395M
营业利润率%13.6%14.0%14.3%13.2%12.5%10.0%6.4%7.0%7.1%7.4%9.4%11.3%10.8%9.1%8.2%8.0%10.1%
净利$1.4B$1.4B$1.4B$1.4B$1.1B$966M$279M$191M$259M$1.3B$115M$387M$356M$227M$178M$242M$161M
净利润率 %8.1%8.3%8.9%9.1%7.6%7.0%2.5%1.7%2.5%13.5%1.7%6.8%6.5%4.4%3.6%5.6%4.1%
EBITDA$3.5B$3.5B$3.5B$3.3B$2.9B$2.8B$2.1B$2.0B$1.9B$1.7B$849M$768M$723M$554M$500M$386M$467M
每股收益(EPS)$8.05$7.84$7.49$7.29$5.72$4.95$1.43$0.96$1.24$5.88$0.76$3.08$2.72$1.77$1.39$1.90$1.26
已发行股数 (M)169M174M183M186M191M195M195M200M208M223M152M126M131M128M128M128M128M

来源:公司公开报告(SEC)。在依赖任何数字前请核对 SEC EDGAR。

资产负债表、现金流、季度数据与完整财务比率见 IQV 交互式查看器。 /companies/us/IQV

类似公司

本网站信息仅用于教育与参考,不构成投资建议。不发布目标价或买卖建议。

English version →全部股票

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.